Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.01.09.22268963: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent.
Consent: The study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations: This study has several …
SciScore for 10.1101/2022.01.09.22268963: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent.
Consent: The study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations: This study has several limitations. The setting was a single health system; while large and representing both urban and rural settings and community and academic hospitals, it is geographically limited to one US state. Our sample had relatively low racial and ethnic minority representation, limiting our ability to detect differences across these key subgroups. While we used statewide data for mortality and vaccination status, hospitalizations were collected only within this single health system. If mAb-untreated patients were also less likely to be seen in the health system for other services (hence, more likely to be hospitalized elsewhere), this may bias our results toward the null. We also relied on EHR data, including manual chart reviews, which may have missing or inaccurate information about the presence of chronic conditions.21 These factors might have limited our ability to detect the impact of mAb treatment, especially between subgroups. Our EHR data does not contain information on SARS-CoV-2 variants at the patient level, so variant phases are presented chronologically. However, during Colorado’s Delta phase more than 99% of sequenced SARS-CoV-2 was Delta variant.22 Our large sample size allowed the detection of meaningful benefits of mAb therapy for most subgroups, but the study could not detect potentially relevant differences between subgroups. Our propensity scoring method achieved excellent matching between mAb-treated and mAb-untreated patient gro...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
